# Atomoxetine in Melanocortin Obesity Syndrome

> **NCT06899178** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 20 (estimated)

## Conditions studied

- Melanocortin Obesity Syndrome
- MCOS

## Interventions

- **DRUG:** Atomoxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06899178
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04
- **Primary completion:** 2028-07
- **Final completion:** 2028-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06899178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06899178, "Atomoxetine in Melanocortin Obesity Syndrome". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06899178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*